**Nomination forms for requesting the assessment of a condition for addition to or removal from newborn bloodspot screening**

**Overview**

This document contains the nomination forms provided in the [*Newborn Bloodspot Screening National Policy Framework*](https://www.health.gov.au/health-topics/cancer#cancer-screening-programs)(the Framework) and described in Policy Area 5: Decision-making process. These forms must be completed in order to request the assessment of a condition for addition to or removal from newborn bloodspot screening.

Before submitting a nomination form, please consider the following information.

**Completing a nomination form**

The Standing Committee on Screening (SCoS) will consider conditions for assessment once a year. Nomination forms must be completed and submitted to [SCoS@health.gov.au](mailto:SCoS@health.gov.au) by **no later than 1 November** each year. Nominations received after this date will be considered as part of the following year’s submissions.

Anyone in Australia can nominate a condition (either for addition to screening or removal from screening) by completing the appropriate nomination form. It is recommended that nominees seek the advice and guidance of an Australian newborn bloodspot screening program prior to completing the form. This will help to ensure that conditions appropriate for nomination and assessment have not already been considered for inclusion, and reduce the chance of duplication if multiple groups or jurisdictions are working on similar applications. Contact details for the newborn bloodspot screening programs may be sought from the national Newborn Bloodspot Screening Program Management Committee, via the SCoS email address listed above.

**Consideration of the nomination form**

Once the completed nomination forms have been received, the Program Management Committee will make an initial assessment of all applications and provide a recommendation to SCoS as to which of the nominated conditions merit more detailed assessment. The recommendation reached by the Program Management Committee is primarily based on the information provided in the nomination forms. As such, it is important that the nomination form is as complete, comprehensive and accurate in its responses as possible. If insufficient evidence is provided in the nomination form, applicants will be advised after this first assessment and may wish to resubmit once all the required information is obtained.

**Recommendations for further assessment**

After considering the recommendation from the Program Management Committee, SCoS will determine which conditions merit detailed review. A detailed review involves an assessment of all available evidence on screening for the condition in question, in line with the decision-making criteria in the Framework.

Progression to and timing of the detailed review are dependent on a number of considerations, including: availability of staff and resources to support the review; the level of evidence available in Australia and internationally; the complexity of the issues being considered; and whether an economic analysis is conducted.

**Final recommendation**

Based on the outcome of the detailed review, SCoS will arrive at one of the final recommendations shown in the box below. If SCoS recommends screening (or ceasing screening) for a condition, the relevant recommendation, accompanied by preliminary cost implications where necessary, will be submitted to the Australian Health Ministers’ Advisory Council (AHMAC) for consideration, via the relevant Principal Committee.

If the recommendation is supported by AHMAC, state and territory governments are then responsible for funding and establishing any other requirements around adding conditions, taking into account local contexts. It may not be appropriate for all states and territories to screen for all conditions due to differences in local populations, priorities and/or feasibility.

**Recommendations that can be made following assessment of the evidence for   
screening a condition**

1. **When considering including a condition in newborn bloodspot screening**, possible recommendations include:

* Screening is recommended.
* A pilot is recommended, and specific issues flagged for investigation.
* Based on the current evidence and understanding of a condition, screening is not recommended at this time. However, there may be merit in revisiting this condition in the future if further evidence emerges.
* Screening is not recommended.

1. **When considering removing a condition currently screened**, possible recommendations include:

* Continue screening.
* Cease screening.

**More information**

For more information regarding the decision-making process for adding or removing conditions from newborn bloodspot screening programs, see Policy Area 5: Decision-making process in the [*Newborn Bloodspot Screening National Policy Framework*](https://www.health.gov.au/health-topics/cancer#cancer-screening-programs).

Any specific questions regarding the nomination or assessment process can be submitted to the Program Management Committee, via [SCoS@health.gov.au](mailto:SCoS@health.gov.au).

**Nomination form requesting assessment of a condition for   
*addition to* newborn bloodspot screening**

**Please submit to the Newborn Bloodspot Screening Program Management Committee   
via SCoS@health.gov.au**

**Date received:** (to be completed by secretariat)

|  |  |
| --- | --- |
| **Questions** | **Response** |
| Name of nominator(s) | **REDACTED** |
| Organisation(s) (if applicable) | Australian Sickle Cell Advocacy Inc |
| Contact details (address, phone, email) | **REDACTED** |
| Role(s) (for example, clinician, researcher, parent, advocate etc.) | Advocates and clinicians |
| Condition nominated for assessment (specifying form(s), if applicable) | Sickle Cell Disease |
| OMIM\* or other names for the condition | 603903 |

\*Online Mendelian Inheritance in Man: http://www.omim.org/

***Instructions for completion***

* Please complete as many of the ‘response’ sections within this form as possible, citing relevant references within the text by number, then list and attach all references at section 6.
* It is recommended that a nominee who is not from a newborn bloodspot screening program seeks the advice and guidance of their jurisdiction’s newborn bloodspot screening program regarding the required documentation and evidence in order to make a submission for the addition or removal of a condition.
* When the nomination form is complete, it should be submitted to the Newborn Bloodspot Screening Program Management Committee.

1. **The condition**

*The condition should be a serious health problem that leads to significant morbidity or mortality. There should be a benefit to conducting screening in the newborn period; and the natural history of the condition, including development from latent to declared disease, should be adequately understood.*

| **Guiding questions** | **Response** |
| --- | --- |
| What is the incidence of the condition in Australia? Is this determined clinically or through screening studies in other countries? | * >300,000 babies are born with SCD every year and >100 million have sickle cell trait every year [1] * There are 256 SCD patients in Australian Registry, but true incidence is not known. However, it is expected to raise due to migration. Global number of migrants with HbS increased from 1.6 million in 1960 to 3.6 million in 2000 [2,3]. The incidence is determined by screening. |
| What is the burden of disease associated with the condition, including morbidity and mortality? What is the spectrum of disease—in particular, are there mild or late-onset forms? | The burden of SCD is huge on personal and family level, as well as on community economics. the community. SCD is a chronic debilitating disease with high mortality and a long list of morbidities including, but not limited to: chronic haemolytic anaemia, recurrent vaso-occlusive crisis resulting in multiple organs damage, life threatening acute chest syndrome, aplastic anaemia, acute splenic sequestration, ischaemic stroke and silent infarcts, avascular necrosis of femoral head, priapisme, cognitive impairment and psycho-social harms [1 - 31]. Life expectancy is reduced (54 vs 76 years [8] and 50 - 90% of affected children in low-income countries die before their 5th birthday [16]. Mild forms exist. |
| At what age would the condition usually be detected clinically? | Generally from 6 months of. However complications such as acute splenic sequestartion can occur from 3 months of age with 50% recurrence rate, and encapsulated bacterial infections and can occur from early childhood [5,9]. |
| What are the benefits of early diagnosis and intervention/treatment? (Consider such benefits as early intervention, prevention of symptoms, reduction of disease severity, provision of a definitive diagnosis, emotional and social benefits and provision of information that would assist families with reproductive decision making.) | There is good evidence of the benefits of early diagnosis followed by early intervention. A RCT by Gaston et al showed a 84% reduction in infection in Penicillin prophylaxis group started at 4 months of age vs placebo group [7,25]. A Cochrane review 2002 showed SCD infants on Penicillin prophylaxis had significantly lower risk for pneumococcal infections (odds ratio = 0.37, 95% CI 0.16 - 0.86) [7}. An observational study showed a 10-fold reduction in mortality related to splenic sequestartion when early parental education on spleen size was provided (Edmond et al. 1985) [1]. Additional benefits include pneumococcal conjugated vaccine, prompt clinical intervention for infection or splenic sequestration, early education, access to comprehensive medical care, genetic counselling for future pregnancies. The mortality has dropped by 50% in 1 - 4 years old SCD patients and life expectancy has improved from 14.3 years to in 40's and 50's in USA and Canada since implementation of universal NBS [1]. |
| What are the possible harms of screening and/or early diagnosis? | Potential psycho-social harms due to incidental detection of sickle cell carrier status, of haemoglobinopathies of unknown clinical significance, possible exposure of non-paternity, stigmata, and potential discrimination [5]. |

1. **The test**

*There should be a suitable test protocol to identify the presence of the condition, and the test protocol should be socially and ethically acceptable to health professionals and the public.*

| **Guiding questions** | **Nominator’s response** |
| --- | --- |
| Describe a detailed methodology for the test (for example, tandem mass spectrometry, immunoassay, molecular), including any second-tier testing required. Provide reference to a published methodology and describe any modifications required. | - Two-tiered approach is still used by most NBS programs. The following methodollogies can be used as initial or second-tier screening: High Performance Liquid Chromatology (HPLC), Isoelectric Focusing (IEF), Capillary Electrophoresis (CE). The principle of the above tests is based on the separation of haemoglobin (Hb) species and quantification of their respective fractions from dried blood spot (DBS) or cord blood samples. - A robust quality insurance program, reporting and referral systems must be in place.  - Tandem Mass Spectrometry (MS/MS) has also been used in other countries. We suggest using HPLC and CE/IEF as initial and second-tier screening [1,12,13,14,15,17,18,1920,21,22,23,24] |
| Can the test be performed on the same dried bloodspot specimen that is used currently? If not, what additional sample would be required? | Yes |
| For the proposed testing protocol, comment on the: |  |
| clinical and analytic validity | Good |
| sensitivity | Close to 100% |
| specificity | Close to 100% |
| false positive rate | Close to 0%, but can be increased by prematurity |
| false negative rate | Close to 0%, but can be increased by recent blood transfusion |
| positive predictive value | Close to 100% |
| negative predictive value | Close to 100% |
| What other conditions may be detected (clinical or of unknown significance)? | Sickle cell trait and other haemoglobinopahies |
| What would be the cost of the test? | The cost for HPLC has been reported in USA and Germany between 2 - 6 US $ + costs Labour + Equipment. However in Australia the cost for HPLC ranges between 90 - 100 AU $ |
| If DNA analysis is required, would testing include common mutations, a panel or full sequencing? | Yes, whole exome sequencing (Panel sequencing), targeting the protein-coding portions of the beta globin gene followed by copy number variation analysis of the beta globin locus to determine normal vs sickle cell mutation [20]. |
| What are the potential harms associated with the test protocol? | Potential psychological harms related to non-paternity disclosure, stigmata and discrimination |

1. **The intervention**

*There should be an accepted intervention for patients with recognised disease, and facilities for diagnosis and management should be available so that these services can be offered if there is a positive screening result.*

| **Guiding questions** | **Nominator’s response** |
| --- | --- |
| What diagnostic testing is necessary? Is it available and reliable? What is its associated cost? | - Every abnormal result will require a confirmation by one of the following tests with an alternative principle: HPLC, IEF, CE. MS/MS or DNA-based assay can also be used. These tests are available and reliable.  - DNA-based assay in Victoria costs about 300 AU $. |
| What is the established intervention/treatment for this condition? | Early initiation of Penicillin prophylaxis soon after diagnosis, preferably by 2 months of age and Pneumococcal conjugated vaccine, comprehensive medical care, early parental education, genetic counselling for future pregnancies, and monitoring of complications. Disease modifying therapies: Hydroxyurea, longterm regular transfusion and curative therapy: bone marrow transplant. |
| Do all patients require an intervention or treatment upon diagnosis? If not, can those who require treatment be distinguished from those who do not? | Yes, particularly:   * Early Penicillin prophylaxis and Pneumococcal vaccine * Comprehensive medical care * Parental education and genetic counselling for future pregnancies * Monitoring of complications |
| How effective is the intervention/treatment? (Does it alleviate symptoms, slow/halt progression?) | Very effective   * Good evidence that early intervention prevents complications, particularly encapsulated bacterial infections/sepsis, reduce morbidities and hospital admission requirement, reduced mortality, and has improved life expectancy [1,7,8,9, 12,13,14, 25] * Hydroxurea, longterm regular transfusion, BMT: very effective [31]. |
| What are the impacts on quality of life? | Positive: significant reduction in morbidities and hospital admissions. |
| How urgent is the intervention/treatment? Must it be initiated before symptoms present? | Interventions need to be initiated and implemented early , soon after the diagnosis has bee made, and as indicated. A retrospective cohort study by Rankine-Mullings et al showed 43% and 40% reduction in vaso-occlusive crisis and acute chest syndrome in early care group vs late care group [13]. |
| What are the potential harms of the intervention/treatment? | Generally well tolerated, however some interventions have side-effects, which need to be monitored. |
| What is the cost of the intervention/treatment | It is difficult to accurately determine the cost without knowing the accurate incidence of the disease in Australia for a meaningful costing analysis. |
| What facilities are required to deliver the intervention/treatment? Do current health care facilities in each state and territory have capacity, and are they of sufficient quality, to support the intervention/treatment? Is there equitable access to the intervention/treatment? | In Australia, SCD patients are managed by specialized Haematology Units mainly located within tertiary health facilities, providing a comprehensive medical care model.  Most of the states in Australia have Haematology Units of acceptable standard to support the intervention/treatment, including comprehension medical care of SCD patients. |

1. **Cost-effectiveness**

|  |  |
| --- | --- |
| **Guiding questions** | **Nominator’s response** |
| Provide any available evidence for the cost-effectiveness of screening for this condition, either from Australia or internationally. | A cost-effective analysis using a Markov simulation model by Panepinto et al, considering the costs and outcomes associated with the prevention and treatment of sepsis in SCD patients: targeted screening of African American vs  no screening: 6709 $ per additional year of life saved. Universal screening vs targeted screening: 30,760 $ per additional year of life saved. Targeted screening is always cost-effective compared to no screening. Universal  screening always identifies more infants with disease, prevents more deaths, and is cost-effective [27]. |

1. **Any Other Comments**

The demographic threshold for coast-effectiveness occurs if the population at risk live births in a given population reaches about 5% (Springkle et al. 1994). However universal screening in Italy found incidence of 1.16% (0.07% SCD, 0.68% with sickle cell trait) similar to other European countries with high immigration (Martella et al. 2017) [21]. In Berlin pilot study, 14/34,084 returned positive for SCD (4.11/10,000) [19], and in 2016, 431 returned positive in French NBS (Birth prevalence of 1:1836) [21]; both the highest among all targeted diseases in NBS programs in Germany and in France. many European countries have already approved universal NBS for SCD: UK, France, Spain, The Netherlands, Malta [31].

US Preventive Services Task Forces found universal NBS for SCD approved in all 50 states and DC in 2006, to be cost effective [25].

1. **References**

1. El-Haj N, Hoppe C. C. Newborn Screening for SCD in the USA and Canada. Int. J. Neonatal Screen. 2018, 4, 36

2. Russo G, de Franceschi L, Colombatti R, et al. Current challenges in the management of patients with sickle cell disease. A report of the Italian experience. Orphanet Journal of Rare Diseases (2019) 14:120.

3. Piel F. B, Huang Z, Gupta S, et al. Global migration and the changing distribution of sickle cell haemoglobin. A quantitative study of temporal trends between 1960 and 2000. Lancet Glob Health. 2014;2(2):e80-9.

4. Chakravorty S, Williams T. N. Sickle cell disease: a neglected chronic disease of increasing global health importance. Arch Dis Child 2015;100;48-53.

5. Naik R. P, Haywood Jr. Sickle cell trait diagnosis: clinical and social implications. American Society of Hematology 2015.

6. Yusuf H. R, Llyod-Puryear M. A, Grant A. M, et al. Sickle cell disease: The need for a Public Health Agenda. Am J Prev Med 2011;41(654):S376-S383.

7. Vichinsky E, Hurst D, Kleman K, et al. Newborn screening for sickle cell disease. Effect on mortality. Paediatrics. 1988 Jun;81(6):749-755.

8. Gill F. M, Sleeper L. A, Weiner S. J, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood. 1995 July 15,8692): 776-83.

9. Powell R. W. Acute splenic sequestration crisis in sickle cell disease: early detection and treatment. Journal of Surgery. Volume 27, Issue 2, February 1992, pages 215-219.

10. Vichinsky E. P. Comprehensive care in sickle cell disease: its impact on morbidity and mortality. Semin. Hematol. 1991, 28,220-226.

11. Parise L. V, Berliner N. Sickle cell disease: challenges and progress. Blood, 18 February 2016. Volume 127, Number 7.

12. Frempong T, Pearson H. A. Newborn screening coupled with comprehensive follow-up reduced early mortality of sickle cell disease in Connecticut. Connect. Med. 2007, 71, 9-12.

13. Rankine-Mullings A. E, Logan T. M, King L, et al. The risk of acute events among patients with sickle cell disease in relation to early or late initiation of care at a specialist centre: evidence from a retrospective cohort study. BMC Pediatrics (2020) 20:373.

14. Runkel B, Kluppelholz B, Rummer A, et al. Screening for sickle cell disease in newborns: a systematic review. Systematic Reviews (2020) 9:250.

15. Lees C, Davies S. C, Dezateux C. Testing newborn babies for sickle cell disease. Cochrane database of Systematic Reviews 2000, issue 1. Art No.: CD001913.

16. Lubeck D, Agodoa I, Bhakta N, et al. Estimated Life Expectancy and Income of patients with Sickle Cell Disease Compared with Those Without Sickle Cell Disease. JAMA Network Open. 2019;2(11):e1915374.

17. Frommel C. Newborn Screening for Sickle Cell Disease and other Hemoglobinopathies: A Short Review on Classical Laboratory Methods - Isoelectrical Focusing, HPLC, and Capillary Eletrophoresis. Int. J. Neonatal Screen. 2018, 4, 39.

18. Braga J. A. P, Verssimo T. N, Saad S. T. O, et al. Guidelines on neonatal screening and painful vaso-occlusive crisis in sickle cell disease. Rev Bras Hemoter. 2016;38 (2):147 - 157.

19. Frommel C, Brose A, Klein J, et al. Newborn Screening for Sickle Cell Disease: Technical and Legal Aspects of a German Pilot Study with 38,220 participants. BioMed Research International. Volume 2014, Article ID 695828, 10 pages.

20. Alhabi M. Different Methodologies to Characterize and Diagnose Sickle Cell Disease in Both Developed and Developing Nations (2018. Graduate Master's Theses. Capstones, and Culminating Projects. 305.

21. Daniel Y, Elion J, Allaf B, et al. Newborn Screening for Sickle Cell Disease In Europe. Int. J. Neonatal Screen. 2019, 5, 15.

22. Lorey F, Cunningham G, Shafer F, et al. Universal Screening for Hemoglobinopathies Using High-performance Liquid Chromatography: Clinical Results of 2.2 Million Screens. Eur J Hum Genet 1994;2:262-271.

23. Robitaille N, Delvin E. E, Hume H. A. Newborn screening for sickle cell disease: A 1988-2003 Quebec experience. Paediatrics & Child Health, Volume 11, Issue 4, April 2006, Pages 223-227.

24. York D, Mitchell J, Clow C, et al. Newborn screening for sickle cell disease and other hemoglobinopathies: a Canadian pilot study. Clin Invest Med. 1992 Aug; 15(4):376-83.

25. Lin K, Barton B. B. Screening for Hemoglobinopathies in Newborns: Reaffirmation Update for the US. Preventive Services Task Force. AHRQ Publication No. 07-05104-EF-1.

26. Tsevat J, Wong J. B, Pauker S. G, Steinberg M. H, et al. Neonatal screening for sickle cell disease: A cost-effectiveness analysis. The Journal of Paediatrics. Volume 118, Issue 4, P546-554, April 01, 1991.

27. Panepinto J. A, Magid D, Rewers M. J, et al. Universal versus targeted screening of infants for sickle cell disease: A cost-effectiveness analysis. The Journal of Paediatrics. Volume 136. Issue 2. February 2000. Pages 201 - 208.

28. McGannan P. T, Santos B, de Pliveira, et al. Cost-effectiviness of Neonatal screening for Sickle Cell Disease in The Republic of Angola. Blood (2013)122(21):421.

29. Lane P. A. Newborn Screening for Hemoglobin Disorders. <https://sickle.bwh.harvard.edu/screening.html>.

30. Cronin E. K, Normand C, Henthom J. S, Hickman, et al. Costing model for neonatal screening and diagnosis of haemoglobinopathies. Arch Dis Child Fetal Neonatal Ed 1998; 79:F1617.

31. Kapoor S, Little J. A, Pecker H. Advances in the Treatment of Sickle Cell Disease. Mayo Clin Proc. 2018;93(12):1810-1824.